<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://arcnouvel.com/wp-sitemap.xsl" ?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"><url><loc>https://arcnouvel.com/shes-gone-and-done-it-the-inspiring-journey-of-dr-nageatte-ibrahim/</loc><lastmod>2025-09-23T14:56:23+00:00</lastmod></url><url><loc>https://arcnouvel.com/arc-nouvel-showcases-innovation-at-biotechx-usa-in-philadelphia/</loc><lastmod>2025-09-23T14:55:45+00:00</lastmod></url><url><loc>https://arcnouvel.com/6-oncology-drugs-likely-to-receive-fda-approval-in-2026-a-clinical-and-regulatory-analysis/</loc><lastmod>2026-01-15T05:35:00+00:00</lastmod></url><url><loc>https://arcnouvel.com/why-cancer-drugs-fail-fda-approval-how-clinical-trial-teams-can-prevent-rejection-early/</loc><lastmod>2026-01-21T00:47:07+00:00</lastmod></url><url><loc>https://arcnouvel.com/who-is-arc-nouvel/</loc><lastmod>2026-01-23T19:42:51+00:00</lastmod></url><url><loc>https://arcnouvel.com/cancer-vaccines-in-the-checkpoint-era-neoantigens-mrna-and-phase-3-progress/</loc><lastmod>2026-03-09T22:03:00+00:00</lastmod></url><url><loc>https://arcnouvel.com/cancer-vaccine-cmc-strategy-fda-expectations-for-manufacturing-and-regulatory-readiness/</loc><lastmod>2026-01-27T18:49:47+00:00</lastmod></url><url><loc>https://arcnouvel.com/rethinking-the-dark-side-interview-with-dr-scott-pruitt/</loc><lastmod>2026-02-02T22:05:19+00:00</lastmod></url><url><loc>https://arcnouvel.com/fda-accelerated-approval-in-oncology-a-strategic-guide-for-biopharma/</loc><lastmod>2026-02-12T05:36:45+00:00</lastmod></url><url><loc>https://arcnouvel.com/rethinking-the-dark-side-with-dr-ildiko-csiki/</loc><lastmod>2026-02-17T22:57:32+00:00</lastmod></url><url><loc>https://arcnouvel.com/who-is-arc-nouvel-a-conversation-with-dr-gavin-liu-on-cell-therapy-cmc-strategy-and-gmp-manufacturing/</loc><lastmod>2026-02-24T18:13:16+00:00</lastmod></url><url><loc>https://arcnouvel.com/who-is-arc-nouvel-dr-robert-charnas-on-regulatory-strategy-patient-focused-development-and-the-discipline-to-stop/</loc><lastmod>2026-02-26T16:20:20+00:00</lastmod></url><url><loc>https://arcnouvel.com/who-is-arc-nouvel-dr-vivian-li-on-strategy-risk-and-value-in-clinical-development/</loc><lastmod>2026-02-26T16:30:49+00:00</lastmod></url><url><loc>https://arcnouvel.com/fda-project-optimus-the-right-dose-in-oncology-drug-development/</loc><lastmod>2026-03-03T19:09:57+00:00</lastmod></url><url><loc>https://arcnouvel.com/what-it-takes-to-lead-at-the-top-jill-desimone-on-purpose-trust-and-the-human-side-of-pharma-leadership/</loc><lastmod>2026-03-20T16:51:36+00:00</lastmod></url><url><loc>https://arcnouvel.com/ai-generated-control-arms-in-clinical-trials-evidence-opportunities-and-strategic-considerations/</loc><lastmod>2026-03-26T19:35:01+00:00</lastmod></url><url><loc>https://arcnouvel.com/oncology-trial-recruitment-in-the-age-of-ai-strategic-insights-for-clinical-development-leaders/</loc><lastmod>2026-03-26T19:44:13+00:00</lastmod></url><url><loc>https://arcnouvel.com/precision-medicine-through-the-patient-lens-the-wondrlink-impact/</loc><lastmod>2026-04-06T17:29:57+00:00</lastmod></url></urlset>
